Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines

This article was originally published here

Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said

The post Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply